Genelux Q1 net loss widens, misses analyst expectations

Genelux

07/05/2026 21:58

Overview

US immuno-oncology firm's Q1 net loss widened, missing analyst expectations

Q1 loss from operations also missed analyst expectations

Operating expenses rose due to increased clinical trial and employee costs

Outlook

Genelux expects topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer trial in 2H26

Company anticipates additional updates from systemic lung cancer programs throughout 2026

Genelux expects current cash to fund operations into 1Q27

Result Drivers

CLINICAL TRIAL COSTS - Higher R&D expenses were primarily driven by increased costs associated with the Phase 3 OnPrime/GOG-3076 registration trial and related clinical and regulatory activities

EMPLOYEE COMPENSATION - General and administrative expense increase was mainly due to higher employee compensation and related expenses

Company press release: ID:nGNX5NVylw

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Miss
-$8.93 mln
-$8.45 mln (5 Analysts)
Q1 Income from Operations
Miss
-$9.17 mln
-$8.56 mln (5 Analysts)
Q1 Operating Expenses
$9.17 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Genelux Corp is $16.00, about 457.5% above its May 6 closing price of $2.87

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)